Gesynta Pharma Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $36.8M

  • Investors
  • 16

Gesynta Pharma General Information

Description

Developer of a clinical-stage pharmaceutical portfolio designed to treat inflammatory diseases by inhibiting pro-inflammatory pathways. The company offers selective enzyme-targeting drug candidates with favorable safety and pharmacological profiles, enabling patients with inflammatory conditions such as endometriosis to experience non-hormonal symptom relief and improved quality of life.

Contact Information

Website
www.gesynta.se
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Wallingatan 24
  • 111 24 Stockholm
  • Sweden
+46 073-383
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • Wallingatan 24
  • 111 24 Stockholm
  • Sweden
+46 073-383

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gesynta Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 21-Oct-2025 $36.8M Completed Clinical Trials - Phase 2
8. Early Stage VC 31-Dec-2021 Completed Clinical Trials - General
7. Early Stage VC 07-Jul-2020 Completed Clinical Trials - General
6. Seed Round 04-Apr-2019 Completed Startup
5. Grant 01-Dec-2018 Completed Startup
4. Grant 18-May-2018 Completed Startup
3. Accelerator/Incubator 27-Apr-2018 Completed Startup
2. Angel (individual) 26-Feb-2018 $2.9M $2.9M Completed Startup
1. Accelerator/Incubator 01-Jan-2018 Completed Startup
To view Gesynta Pharma’s complete valuation and funding history, request access »

Gesynta Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 90,091 $74.19 $74.19 1x $74.19 24.27%
Ordinary 38,747 $65.85 $65.85 1x $65.85 10.44%
To view Gesynta Pharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Gesynta Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a clinical-stage pharmaceutical portfolio designed to treat inflammatory diseases by inhibiting pro-inflamm
Drug Discovery
Stockholm, Sweden
11 As of 2022

Shanghai, China
 

Newtown, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gesynta Pharma Competitors (15)

One of Gesynta Pharma’s 15 competitors is Hope Medicine, a Venture Capital-Backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Hope Medicine Venture Capital-Backed Shanghai, China
Onconova Therapeutics Formerly VC-backed Newtown, PA
Neurocrine Biosciences Formerly VC-backed San Diego, CA
GeneScience Pharmaceutical Corporation Changchun, China
Nippon Shinyaku Corporation Kyoto, Japan
You’re viewing 5 of 15 competitors. Get the full list »

Gesynta Pharma Patents

Gesynta Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202510775-D0 New treatment methods Pending 03-Jul-2025
AU-2023332204-A1 Methods for the treatment or prophylaxis of endometriosis Pending 01-Sep-2022
EP-4580625-A1 Methods for the treatment or prophylaxis of endometriosis Pending 01-Sep-2022
US-20260146029-A1 Methods for the treatment or prophylaxis of endometriosis Pending 01-Sep-2022
WO-2024047229-A1 Methods for the treatment or prophylaxis of endometriosis Inactive 01-Sep-2022 A61K31/4184
To view Gesynta Pharma’s complete patent history, request access »

Gesynta Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gesynta Pharma Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amboy Street Ventures Venture Capital Minority
Catalyze-Capital Venture Capital Minority
CTI Life Sciences Fund Venture Capital Minority
Foreground Capital Venture Capital Minority
HealthCap Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Gesynta Pharma Investments (1)

Gesynta Pharma’s most recent deal was a Corporate Asset Purchase with Orexo (OX-MPI Project). The deal was made on 29-Sep-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Orexo (OX-MPI Project) 29-Sep-2017 Corporate Asset Purchase Buildings and Property
To view Gesynta Pharma’s complete investments history, request access »

Gesynta Pharma FAQs

  • When was Gesynta Pharma founded?

    Gesynta Pharma was founded in 2017.

  • Where is Gesynta Pharma headquartered?

    Gesynta Pharma is headquartered in Stockholm, Sweden.

  • What is the size of Gesynta Pharma?

    Gesynta Pharma has 11 total employees.

  • What industry is Gesynta Pharma in?

    Gesynta Pharma’s primary industry is Drug Discovery.

  • Is Gesynta Pharma a private or public company?

    Gesynta Pharma is a Private company.

  • What is Gesynta Pharma’s current revenue?

    The current revenue for Gesynta Pharma is .

  • How much funding has Gesynta Pharma raised over time?

    Gesynta Pharma has raised $77.9M.

  • Who are Gesynta Pharma’s investors?

    Amboy Street Ventures, Catalyze-Capital, CTI Life Sciences Fund, Foreground Capital, and HealthCap are 5 of 16 investors who have invested in Gesynta Pharma.

  • Who are Gesynta Pharma’s competitors?

    Hope Medicine, Onconova Therapeutics, Neurocrine Biosciences, GeneScience Pharmaceutical, and Nippon Shinyaku are some of the 15 competitors of Gesynta Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process